An interventional study of Ambulatory ECG monitoring in Aortic Stenosis and Conduction Disturbances, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 22nd largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2026, is one of 49 with no phase, reaches primary completion later than 26 of the 35 other live ones, and was the 86th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:
Kardigan, Inc. · Sites in Canada, United States
Ages 50+
World Health Research Inc. · Sites in Canada, Australia, Colombia and 5 more countries
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in Canada
Ages 18–80
Novartis Pharmaceuticals · Sites in Canada, United States, Austria and 12 more countries
Ages 50–80
Edwards Lifesciences · Sites in Canada, United States
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 754 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 60 interventional studies, 320 across the 27 observational. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 87 have an industry lead sponsor. The 10 most frequent:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval is the lead sponsor of 15 studies on the registry; 9 are open to participants now.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval has 5 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Aortic Valve Stenosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06991517World Health Research Inc.A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm | 2026-12 |
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT04464655McGill University Health Centre/Research Institute of the McGill University Health CentreA 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease | 2026-12-19 |
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stroke within 1 year compared with standard post-discharge care. Patients undergoing successful TAVI without permanent pacemaker implantation and presenting with at least one ECG conduction abnormality at hospital discharge will be randomized to receive either ambulatory ECG monitoring or standard follow-up. All participants will undergo routine clinical follow-up at 30 days and 1 year after TAVI.
Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis. Despite advances in transcatheter heart valve technology and procedural techniques, conduction disturbances remain among the most frequent complications following TAVI. High-grade atrioventricular block, complete heart block, and new-onset bundle branch block may occur after the procedure and can lead to delayed permanent pacemaker implantation or life-threatening arrhythmic events. The increasing adoption of minimalist TAVI pathways with hospital discharge within 24-72 hours raises concerns that clinically significant arrhythmias may develop after discharge and remain undetected.
Ambulatory electrocardiographic (ECG) monitoring provides continuous rhythm surveillance during daily activities and enables the early detection of both symptomatic and asymptomatic bradyarrhythmias and tachyarrhythmias. Previous observational studies have demonstrated that clinically significant bradyarrhythmias occur in approximately 5-10% of patients during the first weeks after TAVI, particularly among those with baseline or new-onset conduction abnormalities. Ambulatory ECG monitoring has also identified previously unrecognized atrial fibrillation, allowing timely initiation of anticoagulation therapy in patients at high risk of thromboembolic events.
Although several prospective studies have evaluated ambulatory ECG monitoring after TAVI, most have been observational and were designed primarily to describe the incidence of post-procedural arrhythmias rather than to assess their impact on clinical outcomes. Preliminary evidence from the RECORD pilot study suggested that systematic ambulatory ECG monitoring after hospital discharge was associated with earlier identification and treatment of clinically significant arrhythmias and a reduction in the composite of sudden death, symptomatic arrhythmic events, and stroke during 1-year follow-up, with the greatest benefit observed among patients with conduction abnormalities at hospital discharge.
This randomized trial has been designed to provide definitive evidence regarding the clinical value of systematic ambulatory ECG monitoring after TAVI in patients at increased risk of post-procedural conduction disturbances. The study will evaluate whether early detection and management of clinically significant arrhythmias can improve clinical outcomes during the year following the procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo ambulatory ECG monitoring at hospital discharge following TAVI. Continuous ECG monitoring will be performed for 14 days using an ambulatory ECG monitoring device. Clinically significant bradyarrhythmias or tachyarrhythmias detected during monitoring will be reviewed and managed according to clinical practice, including appropriate therapeutic interventions when indicated.
Device: Ambulatory ECG monitoring
Participants will receive standard post-TAVI care without systematic ambulatory ECG monitoring at hospital discharge. Clinical follow-up will be performed according to routine practice.
Participants randomized to the intervention arm will undergo systematic ambulatory ECG monitoring at hospital discharge following the TAVI procedure. A wearable ambulatory ECG monitoring device will be applied for continuous rhythm monitoring during a 14-day period. The device will allow detection of clinically significant bradyarrhythmias and tachyarrhythmias. Detected arrhythmic events will be reviewed by the study team, and appropriate clinical management, including further evaluation or therapeutic intervention, will be performed according to the nature of the detected abnormality and standard clinical practice.
Rate of the combined endpoint (sudden death, symptomatic arrhythmias or stroke)
Composite endpoint including sudden death, symptomatic arrhythmias, or stroke.
Time frame: Within the year following the TAVI procedure
Incidence of sudden death
Sudden death
Time frame: 1 year after TAVI
Incidence of symptomatic arrhythmias
All symptomatic arrhythmias events
Time frame: 1 year after TAVI
Incidence of stroke
All stroke events
Time frame: 1 year after TAVI
Incidence of PPI
Number of patients with PPI
Time frame: 30 days after TAVI
Incidence of PPI
Number of patients with PPI
Time frame: 1 year after TAVI
Incidence of the combined endpoint (sudden death, symptomatic arrhythmias or stroke) at 30 days
Composite endpoint including sudden death, symptomatic arrhythmias, or stroke.
Time frame: 30 days after TAVI
Incidence of sudden death
Sudden death
Time frame: 30 days after TAVI
Incidence of symptomatic arrhytmias
All symptomatic arrhythmias events
Time frame: 30 days after TAVI
Incidence of stroke
All stroke events
Time frame: 30 days after TAVI
Incidence of the combined endpoint (sudden death, symptomatic arrhythmias, stroke) according to patient sex
Composite endpoint including sudden death, symptomatic arrhythmias, or stroke, analyzed according to patient sex.
Time frame: 1 year after TAVI
Incidence of the combined endpoint of sudden death, symptomatic arrhythmias, or stroke) according to ECG abnormalities
Composite endpoint including sudden death, symptomatic arrhythmias, or stroke, analyzed according to ECG abnormality status (pre-existing versus new-onset after TAVI).
Time frame: 1 year after TAVI
Incidence of the combined endpoint according to baseline ECG abnormality type
Composite endpoint (sudden death, symptomatic arrhythmias, or stroke) analyzed according to the type of ECG abnormality present before TAVI.
Time frame: 1 year after TAVI
Incidence of sudden death according to baseline ECG abnormality type
Sudden death analyzed according to the type of ECG abnormality present before TAVI.
Time frame: 1 year after TAVI
Incidence of symptomatic arrhythmias according to baseline ECG abnormality type
Symptomatic arrhythmias according to the type of ECG abnormality present before TAVI.
Time frame: 1 year after TAVI
Incidence of stroke according to baseline ECG abnormality type
Stroke according to the type of ECG abnormality present before TAVI.
Time frame: 1 year after TAVI
Incidence of the combined endpoint according to discharge ECG abnormality type
Composite endpoint (sudden death, symptomatic arrhythmias, or stroke) according to the type of ECG abnormality present at hospital discharge.
Time frame: 1 year after TAVI
Incidence of sudden death according to discharge ECG abnormality type
Sudden death according to the type of ECG abnormality present at hospital discharge.
Time frame: 1 year after TAVI
Incidence of symptomatic arrhythmias according to discharge ECG abnormality type
Symptomatic arrhythmias according to the type of ECG abnormality present at hospital discharge.
Time frame: 1 year after TAVI
Incidence of stroke according to discharge ECG abnormality type
Stroke according to the type of ECG abnormality present at hospital discharge.
Time frame: 1 year after TAVI
Change in quality of life
Quality of life assessed using the EQ-5D-5L questionnaire.
Time frame: Baseline to 1 year after TAVI
Percentage of ventricular pacing
Ventricular pacing burden in participants with permanent pacemakers.
Time frame: 1 year after TAVI
Incidence of all-cause mortality
All-cause mortality
Time frame: 30 days after TAVI
Incidence of cardiovascular mortality
Cardiovascular mortality
Time frame: 30 days after TAVI
Incidence of all-cause mortality
All cause mortality
Time frame: 1 year after TAVI
Incidence of cardiovasculare mortality
Cardiovascular mortality
Time frame: 1 year after TAVI
Plan to share: Undecided — A decision regarding IPD sharing has not yet been made. Following study completion, requests for access to de-identified individual participant data may be considered by the sponsor on a case-by-case basis, subject to ethical, legal, and institutional requirements.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 26 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval